

Lidings advised on the acquisition of Baxter's Continuous Renal Replacement Therapy Business by Nikkiso

Nikkiso America, Inc. announced it has completed the acquisition of Baxter International Inc.'s legacy Continuous Renal Replacement Therapy (CRRT) business. The deal involved several dozen jurisdictions. Lidings was engaged to support the transaction in Russia.

As state in a press-released published by Nikkiso, CRRT is a therapy used primarily for patients in the ICU in need of blood purification due to acute kidney injury or fluid overload. Nikkiso has been the original equipment manufacturer of the AquariusTM CRRT System for Baxter and is extending its presence in the acute renal failure marketplace. The company is a global market leader in chronic renal failure equipment.

"Participation in a multi-jurisdictional transaction is yet another milestone in the development of Lidings' pharmaceutical practice. Being engaged by clients not yet represented in the Russian market demonstrates that our industrial expertise is recognized far beyond Russia", commented counsel, co-head of pharmaceutical industry practice at Lidings Sergey Patrakeev who led the transaction team for the project.